Exact Mass: 405.1792
Exact Mass Matches: 405.1792
Found 500 metabolites which its exact mass value is equals to given mass value 405.1792
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Clomifene
Clomifene is only found in individuals that have used or taken this drug. It is a triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. [PubChem]Clomifene has both estrogenic and anti-estrogenic properties, but its precise mechanism of action has not been determined. Clomifene appears to stumulate the release of gonadotropins, follicle-stimulating hormone (FSH), and leuteinizing hormone (LH), which leads to the development and maturation of ovarian follicle, ovulation, and subsequent development and function of the coprus luteum, thus resulting in pregnancy. Gonadotropin release may result from direct stimulation of the hypothalamic-pituitary axis or from a decreased inhibitory influence of estrogens on the hypothalamic-pituitary axis by competing with the endogenous estrogens of the uterus, pituitary, or hypothalamus. Clomifene has no apparent progestational, androgenic, or antrandrogenic effects and does not appear to interfere with pituitary-adrenal or pituitary-thyroid function. G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03G - Gonadotropins and other ovulation stimulants > G03GB - Ovulation stimulants, synthetic D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen D012102 - Reproductive Control Agents > D005299 - Fertility Agents C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
Roseoflavin
A benzopteridine that is riboflavin in which the methyl group at position 8 is substituted by a dimethylamino group.
Toremifene
Toremifene is only found in individuals that have used or taken this drug. It is a first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. [PubChem]Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, in other words, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. Toremifene may also inhibit tumor growth through other mechanisms, such as induction of apoptosis, regulation of oncogene expression, and growth factors. L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BA - Anti-estrogens D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Nebivolol
Nebivolol is only found in individuals that have used or taken this drug. It is a highly cardioselective vasodilatory beta1 receptor blocker used in treatment of hypertension. In most countries, this medication is available only by prescription. [Wikipedia]Nebivolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Nebivolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. At high enough concentrations, this drug may also bind beta 2 receptors. C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Imidapril
Imidapril, also known as Tanatril (trade name), belongs to a class of long-acting, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitors (PMID: 12177688). It is a prodrug that is widely used in the treatment of mild to moderate essential hypertension (PMID: 17547476). A prodrug is a drug that must be metabolized in the body (via the gut or the liver) to become active. Imidapril is also prescribed to treat chronic congestive heart failure (CHF), acute myocardial infarction (AMI), and diabetic nephropathy (PMID: 12177688, 17094051). It functions through preventing angiotensin II formation, via inhibition of the angiotensin-converting enzyme (ACE), that results in reduction of peripheral resistance and a reduction in systemic blood pressure (BP) (PMID: 17547476). Imidapril is only found in individuals that have used or taken this drug. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
Febarbamate
M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents > M03BA - Carbamic acid esters C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
Nifekalant
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
Nitro-prednisolone
Taltirelin
nifekalant
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C93038 - Cation Channel Blocker
(3E,5aS,10bR)-6,10b,11,11a-tetrahydro-11a-hydroxy-3-(1H-imidazol-5-ylmethylidene)-10b-(2-methylbut-3-en-2-yl)-2H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4(3H,5aH)-dione|16-hydroxyroquefortine C
12,13-Dihydro-1,2-dimethoxy-6-acetonyl-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridine
(E)-4-hydroxy-2-(hydroxymethyl)but-2-enenitrile 4-O-beta-D-glucopyranoside 6?-O-(2?S,3?R)-2?-ethyl-2?,3?-dihydroxybutyrate|microtropin D
5-acetoxymethyl-5,7,8,13,13b,14-hexahydro-indolo[2,3:3,4]pyrido[1,2-b][2,7]naphthyridine-1-carboxylic acid methyl ester|Cadamin-D-Acetat
Toremifene
L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BA - Anti-estrogens D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Febarbamate
M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents > M03BA - Carbamic acid esters C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
Imidapril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Ala Ala Met Asn
Ala Ala Asn Met
Ala Cys Gly Arg
Ala Cys Asn Val
Ala Cys Arg Gly
Ala Cys Val Asn
Ala Gly Cys Arg
Ala Gly Lys Met
Ala Gly Met Lys
Ala Gly Met Gln
Ala Gly Gln Met
Ala Gly Arg Cys
Ala Lys Gly Met
Ala Lys Met Gly
Ala Met Ala Asn
Ala Met Gly Lys
Ala Met Gly Gln
Ala Met Lys Gly
Ala Met Asn Ala
Ala Met Gln Gly
Ala Asn Ala Met
Ala Asn Cys Val
Ala Asn Met Ala
Ala Asn Thr Thr
Ala Asn Val Cys
Ala Gln Gly Met
Ala Gln Met Gly
Ala Gln Ser Thr
Ala Gln Thr Ser
Ala Arg Cys Gly
Ala Arg Gly Cys
Ala Ser Gln Thr
Ala Ser Thr Gln
Ala Thr Asn Thr
Ala Thr Gln Ser
Ala Thr Ser Gln
Ala Thr Thr Asn
Ala Val Cys Asn
Ala Val Asn Cys
Cys Ala Gly Arg
Cys Ala Asn Val
Cys Ala Arg Gly
Cys Ala Val Asn
Cys Gly Ala Arg
Cys Gly Ile Asn
Cys Gly Lys Val
Cys Gly Leu Asn
Cys Gly Asn Ile
Cys Gly Asn Leu
Cys Gly Gln Val
Cys Gly Arg Ala
Cys Gly Val Lys
Cys Gly Val Gln
Cys Ile Gly Asn
Cys Ile Asn Gly
Cys Lys Gly Val
Cys Lys Val Gly
Cys Leu Gly Asn
Cys Leu Asn Gly
Cys Asn Ala Val
Cys Asn Gly Ile
Cys Asn Gly Leu
Cys Asn Ile Gly
Cys Asn Leu Gly
Cys Asn Val Ala
Cys Gln Gly Val
Cys Gln Val Gly
Cys Arg Ala Gly
Cys Arg Gly Ala
Cys Val Ala Asn
Cys Val Gly Lys
Cys Val Gly Gln
Cys Val Lys Gly
Cys Val Asn Ala
Cys Val Gln Gly
Asp Gly Lys Ser
Asp Gly Ser Lys
Asp Lys Gly Ser
Asp Lys Ser Gly
Asp Ser Gly Lys
Asp Ser Lys Gly
Gly Ala Cys Arg
Gly Ala Lys Met
Gly Ala Met Lys
Gly Ala Met Gln
Gly Ala Gln Met
Gly Ala Arg Cys
Gly Cys Ala Arg
Gly Cys Ile Asn
Gly Cys Leu Asn
Gly Cys Asn Ile
Gly Cys Asn Leu
Gly Cys Gln Val
Gly Cys Arg Ala
Gly Cys Val Gln
Gly Asp Lys Ser
Gly Asp Ser Lys
Gly Gly Ser Trp
Gly Gly Trp Ser
Gly Ile Cys Asn
Gly Ile Asn Cys
Gly Lys Asp Ser
Gly Lys Ser Asp
Gly Leu Cys Asn
Gly Leu Asn Cys
Gly Met Ala Gln
Gly Met Gln Ala
Gly Asn Cys Ile
Gly Asn Cys Leu
Gly Asn Ile Cys
Gly Asn Leu Cys
Gly Gln Ala Met
Gly Gln Cys Val
Gly Gln Met Ala
Gly Gln Thr Thr
Gly Gln Val Cys
Gly Arg Ala Cys
Gly Arg Cys Ala
Gly Arg Ser Ser
Gly Ser Asp Lys
Gly Ser Gly Trp
Gly Ser Lys Asp
Gly Ser Arg Ser
Gly Ser Ser Arg
Gly Ser Trp Gly
Gly Thr Gln Thr
Gly Thr Thr Gln
Gly Val Cys Gln
Gly Val Gln Cys
Gly Trp Gly Ser
Gly Trp Ser Gly
Ile Cys Gly Asn
Ile Cys Asn Gly
Ile Gly Cys Asn
Ile Gly Asn Cys
Ile Asn Cys Gly
Ile Asn Gly Cys
Lys Asp Gly Ser
Lys Asp Ser Gly
Lys Gly Asp Ser
Lys Gly Ser Asp
Lys Ser Asp Gly
Lys Ser Gly Asp
Leu Cys Gly Asn
Leu Cys Asn Gly
Leu Gly Cys Asn
Leu Gly Asn Cys
Leu Asn Cys Gly
Leu Asn Gly Cys
Met Ala Ala Asn
Met Ala Gly Gln
Met Ala Asn Ala
Met Ala Gln Gly
Met Gly Ala Gln
Met Gly Gln Ala
Met Asn Ala Ala
Met Gln Ala Gly
Met Gln Gly Ala
Asn Ala Ala Met
Asn Ala Cys Val
Asn Ala Met Ala
Asn Ala Thr Thr
Asn Ala Val Cys
Asn Cys Ala Val
Asn Cys Gly Ile
Asn Cys Gly Leu
Asn Cys Ile Gly
Asn Cys Leu Gly
Asn Cys Val Ala
Asn Gly Cys Ile
Asn Gly Cys Leu
Asn Gly Ile Cys
Asn Gly Leu Cys
Asn Ile Cys Gly
Asn Ile Gly Cys
Asn Leu Cys Gly
Asn Leu Gly Cys
Asn Met Ala Ala
Asn Ser Ser Val
Asn Ser Val Ser
Asn Thr Ala Thr
Asn Thr Thr Ala
Asn Val Ala Cys
Asn Val Cys Ala
Asn Val Ser Ser
Gln Ala Gly Met
Gln Ala Met Gly
Gln Ala Ser Thr
Gln Ala Thr Ser
Gln Cys Gly Val
Gln Cys Val Gly
Gln Gly Ala Met
Gln Gly Cys Val
Gln Gly Met Ala
Gln Gly Thr Thr
Gln Gly Val Cys
Gln Met Ala Gly
Gln Met Gly Ala
Gln Ser Ala Thr
Gln Ser Thr Ala
Gln Thr Ala Ser
Gln Thr Gly Thr
Gln Thr Ser Ala
Gln Thr Thr Gly
Gln Val Cys Gly
Gln Val Gly Cys
Arg Ala Cys Gly
Arg Ala Gly Cys
Arg Cys Ala Gly
Arg Cys Gly Ala
Arg Gly Ala Cys
Arg Gly Cys Ala
Arg Gly Ser Ser
Arg Ser Gly Ser
Arg Ser Ser Gly
Ser Ala Gln Thr
Ser Ala Thr Gln
Ser Asp Gly Lys
Ser Asp Lys Gly
Ser Gly Asp Lys
Ser Gly Gly Trp
Ser Gly Lys Asp
Ser Gly Arg Ser
Ser Gly Ser Arg
Ser Gly Trp Gly
Ser Lys Asp Gly
Ser Lys Gly Asp
Ser Asn Ser Val
Ser Asn Val Ser
Ser Gln Ala Thr
Ser Gln Thr Ala
Ser Arg Gly Ser
Ser Arg Ser Gly
Ser Ser Gly Arg
Ser Ser Asn Val
Ser Ser Arg Gly
Ser Ser Val Asn
Ser Thr Ala Gln
Ser Thr Gln Ala
Ser Val Asn Ser
Ser Val Ser Asn
Ser Trp Gly Gly
Thr Ala Asn Thr
Thr Ala Gln Ser
Thr Ala Ser Gln
Thr Ala Thr Asn
Thr Gly Gln Thr
Thr Gly Thr Gln
Thr Asn Ala Thr
Thr Asn Thr Ala
Thr Gln Ala Ser
Thr Gln Gly Thr
Thr Gln Ser Ala
Thr Gln Thr Gly
Thr Ser Ala Gln
Thr Ser Gln Ala
Thr Thr Ala Asn
Thr Thr Gly Gln
Thr Thr Asn Ala
Thr Thr Gln Gly
Val Ala Cys Asn
Val Ala Asn Cys
Val Cys Ala Asn
Val Cys Gly Gln
Val Cys Asn Ala
Val Cys Gln Gly
Val Gly Cys Gln
Val Gly Gln Cys
Val Asn Ala Cys
Val Asn Cys Ala
Val Asn Ser Ser
Val Gln Cys Gly
Val Gln Gly Cys
Val Ser Asn Ser
Val Ser Ser Asn
Trp Gly Gly Ser
Trp Gly Ser Gly
Trp Ser Gly Gly
Nebivolol
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Epolactaene
[3-(1,3-benzoxazol-2-yl)-2-oxochromen-7-yl] octanoate
(S)-2-((TERT-BUTOXYCARBONYL)AMINO)-3-PHENYLPROPYL 4-METHYLBENZENESULFONATE
N-[4-(2-Methyl-2-propanyl)benzyl]-N-{3-[(methylsulfonyl)amino]be nzyl}carbamimidothioic acid
potassium: 1,2-diethenylbenzene: 1-ethenyl-2-ethyl-benzene: styrene
2,7-Dichloro-Alpha-[(Dibutylamino)Methyl]-9H-Fluorene-4-Methanol
SGI-1776 free base
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Adoprazine
Adoprazine (SLV313) is a full 5-HT1A receptor agonist with a pEC50 of 9 at cloned h5-HT1A receptors. Adoprazine (SLV313) is a full D2 and D3 receptor antagonist with pA2s of 9.3 and 8.9 at hD2 and hD3 receptors, respectively. Adoprazine (SLV313) has the characteristics of atypical antipsychotics[1].
3-(6-chloro-1-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane
2-Chloro-N-[(1-hydroxycycloheptyl)methyl]-5-[1-(2-hydroxyethyl)-5 -methyl-1H-pyrazol-3-yl]benzamide
TERT-BUTYL (2S,3S)-1-(4-(BENZYLOXY)PHENYL)-4-CHLORO-3-HYDROXYBUTAN-2-YLCARBAMATE
(R)-2-(3-(DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4-METHYLPHENOL HYDROBROMIDE
DIETHYL 1,4-DIHYDRO-2,6-DIMETHYL-1,4-DIPHENYL-3,5-PYRIDINEDICARBOXYLATE
Taltirelin
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C76367 - Thyrotropin-Releasing Hormone Analogue D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D002491 - Central Nervous System Agents > D018697 - Nootropic Agents
N-[2-[(2,6-dicyano-4-nitrophenyl)azo]-5-(diethylamino)phenyl]acetamide
(5R)-5-[[3,6-Dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy]hexanoic acid
Methyl 5-[[2-[(3-methylphenyl)methyl]-1-oxo-3,4-dihydroisoquinolin-5-yl]oxymethyl]furan-2-carboxylate
9-Butyl-8-(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine
Clomifene
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03G - Gonadotropins and other ovulation stimulants > G03GB - Ovulation stimulants, synthetic D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen D012102 - Reproductive Control Agents > D005299 - Fertility Agents C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor
7-hydroxy-8-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]-2,2-dimethyl-6-(3-methylbut-2-enyl)chromen-5-olate
(2S,3S,6R)-3-[[2-(2-amino-3-methyl-1,4,5,6-tetrahydropyrimidin-3-ium-6-yl)acetyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2H-pyran-2-carboxylate
2-(4-(4-Chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine
11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1-nitro-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
Ancistrotanzanine A
An isoquinoline alkaloid that is (3S)-6,8-dimethoxy-1,3-dimethyl-3,4-dihydroisoquinoline substituted by a 1-hydroxy-8-methoxy-3-methylnaphthalen-2-yl group at position 5. It is isolated from the leaves of Ancistrocladus tanzaniensis and exhibits antiplasmodial, antileishmanial and antitrypanocidal activities.
3-[[5,6-Bis(4-methoxyphenyl)-4-furo[2,3-d]pyrimidinyl]amino]-1-propanol
N-[2,5-diethoxy-4-[[(2-methylpropylamino)-sulfanylidenemethyl]amino]phenyl]-2-furancarboxamide
N-[2-(3,4-diethoxyphenyl)ethyl]-4-phenoxybenzamide
2-(4-Chlorophenyl)-3-(4-fluorophenyl)-1-(4-morpholinyl)-3-heptanol
(2S,3S,6R)-3-[[2-(2-amino-1-methyl-5,6-dihydro-4H-pyrimidin-4-yl)acetyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2H-pyran-2-carboxylic acid
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
(2S)-2-[(4R,5S)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4R,5R)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
N-[2-[(2R,5S,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
N-[2-[(2S,5S,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(3-methoxyphenyl)urea
1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(3-methoxyphenyl)urea
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8R)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(2R)-2-[(4S,5S)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2R)-2-[(4R,5R)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4S,5S)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
N-[2-[(2S,5R,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
N-[2-[(2R,5R,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
N-[2-[(2R,5R,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
N-[2-[(2R,5S,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
N-[2-[(2S,5S,6S)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
N-[2-[(2S,5R,6R)-5-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]cyclopropanecarboxamide
1-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(3-methoxyphenyl)urea
1-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(3-methoxyphenyl)urea
1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-(4-morpholinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(3-methoxyphenyl)urea
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[4-oxanyl(oxo)methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
(6S,7S,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8S)-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-4-[oxo(pyridin-4-yl)methyl]-1,4-diazabicyclo[4.2.0]octan-2-one
2-(3-Trimethylsilyloxybutoxy)-4-quinolinecarboxylic acid trimethylsilyl ester
1-{17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-20-yl}propan-2-one
1-[(20r)-16,17-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14(19),15,17-octaen-20-yl]propan-2-one
2-[(3r)-6,8-dimethoxy-1,3-dimethyl-3,4-dihydroisoquinolin-7-yl]-8-methoxy-3-methylnaphthalen-1-ol
1-{15,16-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-11-yl}propan-2-one
2-(6,8-dimethoxy-1,3-dimethyl-3,4-dihydroisoquinolin-5-yl)-8-methoxy-3-methylnaphthalen-1-ol
(3s)-5-(4,5-dimethoxy-2-methylnaphthalen-1-yl)-8-methoxy-1,3-dimethyl-3,4-dihydroisoquinolin-6-ol
8-(dimethylamino)-4-hydroxy-7-methyl-10-(2,3,4,5-tetrahydroxypentyl)benzo[g]pteridin-2-one
1-{17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-11-yl}propan-2-one
(±)-6-acetonyldihydrochelerythrine
{"Ingredient_id": "HBIN012152","Ingredient_name": "(±)-6-acetonyldihydrochelerythrine","Alias": "NA","Ingredient_formula": "C24H23NO5","Ingredient_Smile": "CC(=O)CC1C2=C(C=CC(=C2OC)OC)C3=C(N1C)C4=CC5=C(C=C4C=C3)OCO5","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "112","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
ancistrobarterine a
{"Ingredient_id": "HBIN015982","Ingredient_name": "ancistrobarterine a","Alias": "NA","Ingredient_formula": "C25H27NO4","Ingredient_Smile": "CC1CC2=CC(=C(C(=C2C(=N1)C)OC)C3=C4C=CC=C(C4=C(C=C3C)OC)OC)O","Ingredient_weight": "405.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "21539","PubChem_id": "135457480","DrugBank_id": "NA"}
ancistrocladidine
{"Ingredient_id": "HBIN015989","Ingredient_name": "ancistrocladidine","Alias": "NA","Ingredient_formula": "C25H27NO4","Ingredient_Smile": "CC1CC2=CC(=C(C(=C2C(=N1)C)OC)C3=C(C4=C(C=CC=C4OC)C=C3C)O)OC","Ingredient_weight": "405.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1141","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "193880","DrugBank_id": "NA"}